Journal of Clinical Endocrinology & Metabolism, Vol 78, 404-410, Copyright © 1994 by Endocrine Society

ARTICLES

Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome

SA Lieberman, GE Butterfield, D Harrison and AR Hoffman
Medical Service, Department of Veterans Affairs Medical Center, Palo Alto, California 94304.

The loss of lean body mass accompanying acquired immunodeficiency syndrome (AIDS)-associated cachexia is refractory to current modes of therapy. GH and insulin-like growth factor-I (IGF-I) stimulate protein accretion, but resistance to GH action has been reported in malnutrition and infection. We hypothesized that GH resistance occurs in AIDS-associated cachexia, but that treatment with IGF-I would be anabolic. A single injection of GH produced a smaller increase in circulating IGF-I in 21 patients with AIDS compared to that in 23 age- matched controls (141 +/- 15 vs. 194 +/- 15 micrograms/L; P < 0.02), indicating partial GH resistance. Ten subjects received either low or high dose iv recombinant IGF-I 12 h daily for 10 days. Cumulative nitrogen retention was positive for both dosage groups (low dose, 15.42 +/- 6.37 g; high dose, 3.62 +/- 4.15 g), but a significant increase in daily nitrogen retention occurred only in the low dose group on days 2, 4, 5, 6, and 7. Nitrogen balance and protein turnover (estimated by [13C]leucine and [15N] glycine kinetics) during the final 3 days of treatment were unchanged compared to baseline values, confirming the transient nature of the anabolic response. Repeated administration of IGF-I decreased IGF-binding protein-3 levels, producing lower intrainfusion levels of IGF-I and limiting its therapeutic efficacy. The basal metabolic rate increased with high dose IGF-I and may have contributed to the lack of anabolic effect. We conclude that partial GH resistance occurs in AIDS-associated cachexia. Treatment with low dose recombinant IGF-I produces significant, but transient, nitrogen retention. Alternate routes of IGF-I administration or coadministration with GH may prevent attenuation of IGF-I action.

This article has been cited by other articles:

				H. J. Schneider, B. Saller, J. Klotsche, W. Marz, W. Erwa, H.-U. Wittchen, and G. K. Stalla Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects. Eur. J. Endocrinol., May 1, 2006; 154(5): 699 - 706. [Abstract] [Full Text] [PDF]

				P. Crenn, B. Rakotoanbinina, J.-J. Raynaud, F. Thuillier, B. Messing, and J.-C. Melchior Hyperphagia Contributes to the Normal Body Composition and Protein-Energy Balance in HIV-Infected Asymptomatic Men J. Nutr., September 1, 2004; 134(9): 2301 - 2306. [Abstract] [Full Text] [PDF]

				R. Draghia-Akli, K. K. Cummings, A. S. Khan, P. A. Brown, and R. H. Carpenter Effects of plasmid-mediated growth hormone releasing hormone supplementation in young, healthy Beagle dogs J Anim Sci, September 1, 2003; 81(9): 2301 - 2310. [Abstract] [Full Text] [PDF]

				J. C. Lo, K. Mulligan, M. A. Noor, J.-M. Schwarz, R. A. Halvorsen, C. Grunfeld, and M. Schambelan The Effects of Recombinant Human Growth Hormone on Body Composition and Glucose Metabolism in HIV-Infected Patients with Fat Accumulation J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3480 - 3487. [Abstract] [Full Text] [PDF]

				E. Svanberg, R. A. Frost, C. H. Lang, J. Isgaard, L. S. Jefferson, S. R. Kimball, and T. C. Vary IGF-I/IGFBP-3 binary complex modulates sepsis-induced inhibition of protein synthesis in skeletal muscle Am J Physiol Endocrinol Metab, November 1, 2000; 279(5): E1145 - E1158. [Abstract] [Full Text] [PDF]

				N. C. Jackson, P. V. Carroll, D. L. Russell-Jones, P. H. Sonksen, D. F. Treacher, and A. M. Umpleby Effects of glutamine supplementation, GH, and IGF-I on glutamine metabolism in critically ill patients Am J Physiol Endocrinol Metab, February 1, 2000; 278(2): E226 - E233. [Abstract] [Full Text] [PDF]

				K. R. Kritsch, D. J. Huss, and D. M. Ney Greater potency of IGF-I than IGF-I/BP-3 complex in catabolic parenterally fed rats Am J Physiol Endocrinol Metab, February 1, 2000; 278(2): E252 - E262. [Abstract] [Full Text] [PDF]

				N. Mauras, V. Quarmby, and D. C. Bloedow Pharmacokinetics of insulin-like growth factor I in hypopituitarism: correlation with binding proteins Am J Physiol Endocrinol Metab, October 1, 1999; 277(4): E579 - E584. [Abstract] [Full Text] [PDF]

				S.-S. Yeh and M. W Schuster Geriatric cachexia: the role of cytokines Am. J. Clinical Nutrition, August 1, 1999; 70(2): 183 - 197. [Abstract] [Full Text] [PDF]

				A. Vijayan, S. C. Franklin, T. Behrend, M. R. Hammerman, and S. B. Miller Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure Am J Physiol Regulatory Integrative Comp Physiol, April 1, 1999; 276(4): R929 - R934. [Abstract] [Full Text] [PDF]

				S. Grinspoon, C. Corcoran, T. Stanley, L. Katznelson, and A. Klibanski Effects of Androgen Administration on the Growth Hormone-Insulin-Like Growth Factor I Axis in Men with Acquired Immunodeficiency Syndrome Wasting J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4251 - 4256. [Abstract] [Full Text]

				S. Jain, D. W. Golde, R. Bailey, and M. E. Geffner Insulin-Like Growth Factor-I Resistance Endocr. Rev., October 1, 1998; 19(5): 625 - 646. [Abstract] [Full Text]

				I. M. Chapman, M. L. Hartman, K. S. Pieper, E. H. Skiles, S. S. Pezzoli, R. L. Hintz, and M. O. Thorner Recovery of Growth Hormone Release from Suppression by Exogenous Insulin-Like Growth Factor I (IGF-I): Evidence for a Suppressive Action of Free Rather Than Bound IGF-I J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2836 - 2842. [Abstract] [Full Text]

				H. Laurichesse, I. Tauveron, F. Gourdon, L. Cormerais,, C. Champredon, S. Charrier, C. Rochon, S. Lamain,, G. Bayle, H. Laveran, et al. Threonine and Methionine Are Limiting Amino Acids for Protein Synthesis in Patients with AIDS J. Nutr., August 1, 1998; 128(8): 1342 - 1348. [Abstract] [Full Text]

				A. Sandra, M. Boes, B. L. Dake, J. B. Stokes, and R. S. Bar Infused IGF-I/IGFBP-3 complex causes glomerular localization of IGF-I in the rat kidney Am J Physiol Endocrinol Metab, July 1, 1998; 275(1): E32 - E37. [Abstract] [Full Text] [PDF]

				P. J. Garlick, M. A. McNurlan, T. Bark, C. H. Lang, and M. C. Gelato Hormonal Regulation of Protein Metabolism in Relation to Nutrition and Disease J. Nutr., February 1, 1998; 128(2): 356 - 356. [Abstract] [Full Text]

				S. Grinspoon, C. Corcoran, K. Miller, B. M. K. Biller, H. Askari, E. Wang, J. Hubbard, E. J. Anderson, N. Basgoz, H. M. Heller, et al. Body Composition and Endocrine Function in Women with Acquired Immunodeficiency Syndrome Wasting J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1332 - 1337. [Abstract] [Full Text] [PDF]

				E. Wolf, P. M. Jehle, M. M. Weber, H. Sauerwein, A. Daxenberger, B. H. Breier, U. Besenfelder, L. Frenyo, and G. Brem Human Insulin-Like Growth Factor I (IGF-I) Produced in the Mammary Glands of Transgenic Rabbits: Yield, Receptor Binding, Mitogenic Activity, and Effects on IGF-Binding Proteins Endocrinology, January 1, 1997; 138(1): 307 - 313. [Abstract] [Full Text] [PDF]